Supplementary Table 1: Consumption of resources for respiratory support in survivors to discharge home

	1991-92 n=227			1997		2005	
			n=152		n=170		n=217 (reference)
	median (IQR)	Adj^ diff. medians (95% CI) p value	median (IQR)	Adj^ diff. medians (95% CI) p value	median (IQR)	Adj^ diff. medians (95% CI) p value	median (IQR)
All respiratory support ^{&} (days)	30 (17-45)	-35 (-40, -30) p<0.001	48 (31-63)	-24 (-29, -19) p<0.001	44 (25-73)	-19 (-24, -14) p<0.001	70 (51-88)
Invasive ventilation# (days)	21 (8-34)	11 (8, 14) p<0.001	19 (8-32)	5 (1, 8) p=0.01	10 (3-26)	2 (-2, 5) p=0.33	9 (1-30)
Non-invasive ventilation ^{\$} (days)	5 (0-12)	-45 (-49, -41) p<0.001	24 (14-36)	-29 (-33, -25) p<0.001	32 (17-42)	-20 (-24, -16) p<0.001	53 (39-66)
nCPAP (days)	5 (0-12)	-19 (-23, -16) p<0.001	24 (14-36)	-2 (-6, 2) p=0.25	32 (17-42)	6 (3, 10) p=0.001	28 (15-40)
HFNC (days)	-	-	-	-	-	-	23 (15-33)

Supplemental oxygen (days)	62 (34-96) n=226	-7 (-18, 3) p=0.17	47 (12-88)	-17 (-29, -6) p=0.003	67 (20-114) n=167	-9 (-21, 2) p=0.10	84 (44-121) n=184
Primary hospital admission (days)	94 (78-112)	-7 (-12, -3) p=0.002	101 (81-110)	-8 (-13, -3) p=0.003	106 (88- 134)	3 (-2, 8) p=0.19	108 (85-133)

Diff. medians = Difference in medians; IQR = interquartile range; nCPAP = nasal continuous positive airway pressure; HFNC = high flow nasal cannulae.

[^]Adjusted for inborn status (i.e. birth in a tertiary perinatal centre), gestation at birth, sex, birthweight z-score.

[&]Includes positive pressure ventilation via endotracheal tube, high frequency oscillatory ventilation, nCPAP and HFNC.

^{*}Includes positive pressure ventilation via endotracheal tube, high frequency oscillatory ventilation.

^{\$}Includes nCPAP and HFNC.

²⁰¹⁶⁻¹⁷ cohort as a reference for all comparisons.

Supplemental material

Supplementary Table 2: Duration of respiratory support, oxygen therapy, and hospitalisation in those who received intensive care (23 – 27 weeks only)

	1991-92 n=330			1997		2005	2016-17
			ı	n=188	ı	า=226	n=250
	median (IQR)	Adj^ diff. medians (95% CI) p value	median (IQR)	Adj^ diff. medians (95% CI) p value	median (IQR)	Adj^ diff. medians (95% CI) p value	median (IQR)
All respiratory support ^{&} (days)	23 (4-41)	-36 (-41, -30) p<0.001	42 (21-61)	-24 (-30, -18) p<0.001	38 (16-69)	-23 (-29, -17) p<0.001	66 (43-88) n=247
Invasive ventilation# (days)	16 (3-31)	8 (4, 12) p<0.001	15 (5-30)	4 (-1, 8) p=0.11	10 (2-27)	2 (-3, 6) p=0.40	9 (1-29) n=247
Non-invasive ventilation ^{\$} (days)	2 (0-9)	-48 (-52, -44) p<0.001	21 (8-36)	-29 (-34, -25) p<0.001	26 (6-41)	-24 (-28, -20) p<0.001	51 (33-64) n=247
nCPAP (days)	2 (0-9)	-23 (-27, -19) p<0.001	21 (8-36)	-4 (-9, 0.3) p=0.07	26 (6-41)	0.5 (-4, 5) p=0.81	25 (9-39) n=247
HFNC (days)	-	-	-	-	-	-	21 (11-31) n=247
Supplemental oxygen (days)	44 (5-86) n=327	-19 (-33, -5) p=0.01	47 (12-88) n=184	-23 (-39, -7) p=0.01	57 (13-108) n=214	-16 (-31, -1) p=0.04	74 (30-120) n=203

Primary hospital	83 (21-104)	-13 (-20, -6)	93 (69-112)	-9 (-16, -1)	97 (72-128)	-1 (-9, 6)	100 (78-128)
admission* (days)		p<0.001		p=0.03		p=0.72	n=249

Diff. medians = Difference in medians; IQR = interquartile range; nCPAP = nasal continuous positive airway pressure; HFNC = high flow nasal cannulae.

2016-17 cohort as a reference for all comparisons.

[^]Adjusted for inborn status (i.e. birth in a tertiary perinatal centre), gestation at birth, sex, birthweight z-score.

[&]Includes positive pressure ventilation via endotracheal tube, high frequency oscillatory ventilation, nCPAP and HFNC.

[#]Includes positive pressure ventilation via endotracheal tube, high frequency oscillatory ventilation.

^{\$}Includes nCPAP and HFNC.

^{*}Until discharge home.

Supplemental material

	1991-92 n=330			1997		2005	
				n=188	1	n=226	n=250
							(reference)
	n (%)	OR (95% CI) p value	n (%)	OR (95% CI) p value	n (%)	OR (95% CI) p value	n (%)
Survival to discharge home	227 (68.8)	0.24 (0.15, 0.39) p<0.001	151 (80.3)	0.61 (0.35, 1.06) p=0.08	169 (74.8)	0.41 (0.25, 0.68) p=0.001	217 (86.8)
Surfactant	150 (45.5)	0.19 (0.12, 0.28) p<0.001	161 (85.6)	1.26 (0.75, 2.12) p=0.38	202 (89.4)	1.94 (1.13, 3.35) p=0.02	202/247 (81.8)
IVH 3 or 4	44 (13.3)	1.46 (0.85, 2.52) p=0.17	19 (10.1)	1.01 (0.53, 1.94) p=0.97	33 (14.6)	1.56 (0.87, 2.77) p=0.13	27/249 (10.8)
cPVL	21 (6.4)	5.50 (1.63, 18.6) p=0.01	11 (5.9)	5.14 (1.37, 19.3) p=0.02	6 (2.7)	2.25 (0.55, 9.22) p=0.26	3 (1.2)
NEC	30/330 (9.1)	0.57 (0.34, 0.97) p=0.04	12 (6.4)	0.36 (0.18, 0.73) p=0.004	32 (14.2)	0.93 (0.55, 1.58) p=0.80	37 (14.8)
ROP received treatment ^{&}	13/329 (4.0)	0.48 (0.22, 1.03) p=0.06	11/185 (5.9)	0.52 (0.23, 1.18) p=0.12	10/217 (4.6)	0.41 (0.18, 0.96) p=0.04	25/249 (10.0)
BPD (Oxygen at 36 weeks)#	116/237 (49.0)	1.21 (0.80, 1.81) p=0.37	67/152 (44.1)	0.75 (0.47, 1.22) p=0.25	105/181 (58.0)	1.64 (1.07, 2.51) p=0.02	108/220 (49.1)

Postnatal corticosteroids	108 (32.7)	1.21 (0.83, 1.76) p=0.33	80 (42.6)	1.51 (0.98, 2.34) p=0.06	54 (23.9)	0.65 (0.42, 1.01) p=0.06	77 (30.8)
Surgery	77 (23.3)	0.95 (0.64, 1.42) p=0.81	52 (27.7)	1.06 (0.68, 1.68) p=0.79	70 (31.0)	1.36 (0.89, 2.08) p=0.15	62 (24.8)

OR = odds ratio; IVH 3 or 4 = intraventricular haemorrhage grade 3 or 4; cPVL = cystic periventricular leukomalacia; NEC = necrotising enterocolitis Bell Stage 2 or worse; ROP = retinopathy of prematurity; BPD = bronchopulmonary dysplasia.

[^]Adjusted for inborn status (i.e. birth in a tertiary perinatal centre), gestation at birth, sex, birthweight z-score.

[&]Laser or cryotherapy (1991-92, 1997, and 2005); Bevacizumab injections and/or laser therapy (2016-17).

^{*}Denominator – alive at 36 weeks' postmenstrual age

²⁰¹⁶⁻¹⁷ cohort as a reference for all comparisons.

Supplementary Figure 1 Proportions of infants receiving intensive care among all livebirths free of lethal anomalies (Supplementary Figure 1a), those alive at discharge as a percentage of livebirths free of lethal anomalies (Supplementary Figure 1b) and as a percentage of those offered intensive care (Supplementary Figure 1c) in gestational age groups across the four eras. Denominators provided above each bar.

Absolute numbers <5 not provided as per the policy of the Consultative Council on Obstetric and Paediatric Mortality and Morbidity (CCOPMM) in Victoria, from where some of the data were sourced.







